Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine after primary PCI for STEMI
ACTRN12619001616167Phase 4Completed
- Sponsor
- Hamlet Hayrapetyan, FESC
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of trimetazidine in coronary arteriosclerosis and myocardial infarction (MI) (2 arms), sponsored by Hamlet Hayrapetyan, FESC. Primary endpoints: Readmission due to cardiac event within 6 months after initial discharge and Left ventricular ejection fraction at 6 months. Started Jan 2016; status: completed.
02
Drugs
trimetazidine
03
Conditions
coronary arteriosclerosismyocardial infarction (MI)
Beyond the preview
Go deeper on ACTRN12619001616167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001616167.